Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.33 |
| ▸ | LPL | P06858 | 6/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633971 | 0.99 | PDK2 (0.40) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL16633883 | 0.96 | APEX1 (0.40) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL5502877 | 0.92 | LIPG (0.42) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL3789775 | 0.90 | LIPG (0.43) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL3194907 | 0.90 | LIPG (0.43) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL30800031 | 0.90 | LIPG (0.43) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL30274473 | 0.90 | LIPG (0.43) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL6234954 | 0.90 | LIPG (0.43) | PDK2APEX1PCSK9LIPGLPL | |
| SCHEMBL16632979 | 0.90 | APEX1 (0.41) | PDK2APEX1PCSK9 | |
| SCHEMBL16872804 | 0.87 | LIPG (0.40) | PDK2APEX1PCSK9LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2886548-A1 | METHOD FOR PRODUCING BORINIC ACID DERIVATIVE, AND NOVEL BORINIC ACID DERIVATIVE | Manac Inc. (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | MANAC INC. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | ADORA2B, TPSAB1, ACVR2B | PDK2 2287/4885APEX1 551/4885PCSK9 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.